Slides
Page 1
Q1 2026 – Preliminary Results Presentation 27 August 2026
Page 2
This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person‘s officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. Due to rounding, numbers presented throughout this report may not add up precisely to the totals indicated and percentages may not precisely reflect the absolute figures for the same reason. Disclaimer 8/27/2026 Gerresheimer AG – Prelim. Q1 2026 Results Presentation1
Page 3
Q1 2026 Overview
Page 4
Regaining freedom to operate and continuing portfolio & operational transformation Executing on Portfolio Transformation – Post Centor & PPP divestiture, leverage at sustainable <3x level 8/27/2026 Gerresheimer AG – Prelim. Q1 2026 Results Presentation Signed divestitures on 29 July; closing Centor targeted for Nov’26 and PPP for H1 27 Refinancing aligned with closings; deleveraging to sustainable <3x leverage level Re-shaping Portfolio: Grow – Medical Systems, Syringe Systems, Tubular Glas NA; Fix – Tubular Glass Europe; right size SG&A; Sell – Preparing divestiture Moulded Glass Accelerating transformation (gto): Executing EUR 50-70m EBITDA improvement mainly footprint optimization; operational excellence and SG&A efficiencies After cash preservation mode in Q1, expecting result improvement with better H2 vs. H1 3
Page 5
Q1 25 impact of corrections revenues and adjusted EBITDA (EURm) 2025 effects from restatements resulted in Revenues ~unchanged (-0%) and EBITDA (-11%) 8/27/2026 520 519 Q1 2025 old Q1 2025 restated Δ1 Revenues* Adj. EBITDA* -17 91 81 Q1 2025 old Q1 2025 restated Δ10 Corrections consist of • Bill & Hold adjustments in FY24 resulted in Revenues EUR +11m and EBITDA EUR +5m in Q1 25 • Other corrections impacted Q1 25 by EUR -12m in Revenues and by EUR -15m in EBITDA • BaFin investigation ongoing as expected – continuing full cooperation with authorities 17.6% 15.7% 4 11 5 -12 -15 Revenues Adj. EBITDA Bill and Hold Other -1 -10 Gerresheimer AG – Prelim. Q1 2026 Results Presentation * including the business units currently in the sales process.
Page 6
As Reported Revenues, Adjusted EBITDA and Cash Flow; FX as is 8/27/2026 Q1 2025 Prel. Q1 2026 519 524 Revenues* (EURm) Organic growth yoy1 4.4% Adj. EBITDA* (EURm) Q1 with minor sales increase of EUR 5m; Containment & Delivery Systems and Injectable Solutions growth partially offset by Moulded Glass 1 Organically, adjusted for exchange rate effects * including the business units currently in the sales process. Adjusted EBITDA decreased by EUR -15m; cash focus with inventory rigor including temporary production halts impacted earnings 5 81 66 Q1 2025 Prel. Q1 2026 -141 -32 Q1 2025 Prel. Q1 2026 12.6%15.7% Significant FCF improvement YoY ~EUR 110m driven 50/50 by CapEx / WC rigor. Best Q1 FCF result since 2019 Q1 25 with EUR 46m inventory build-up vs. Q1 26 with EUR 5m; a +EUR 41m yoy swing Q1 25 with EUR 113m Net CapEx vs. Q1 26 much reduced EUR 56m; a +EUR 57m yoy swing FCF before M&A* (EURm) Best Q1 FCF before M&A since 2019; Reducing CapEx to Half and avoiding > EUR 40m inventory build-up YoY – yet (EUR 15m) lower EBITDA Q1 2026 deliberately managed for liquidity; targeting better H2 vs. H1 – Publication of final Q1 Financials scheduled for September including quarterly impairment assessment, non-cash relevant Gerresheimer AG – Prelim. Q1 2026 Results Presentation
Page 7
Preliminary Q1 2026 Financial Performance
Page 8
Moulded Glass*Primary Injectable Solutions Containment & Delivery Systems Moulded Glass serves the three markets of pharmaceuticals, cosmetics, and food & beverages Next: Preparing Moulded Glass New Segmentation Q1 onwards - Divestitures accelerating progress towards High Value Primary Packaging and Drug Delivery Solutions 7 Syringe Systems Tubular Glass Primary Packaging Plastics Centor Medical Device Systems Advanced Technologies PPP Centor Medical Device Systems Advanced Technologies Preparing separation and carve out Divestitures Gerresheimer AG – Prelim. Q1 2026 Results Presentation8/27/2026
Page 9
Revenues and Adj. EBITDA growth mainly driven by successful Peachtree Ramp Up in Medical Devices Containment and Delivery Systems – Peachtree Ramp Up Coming Through 8/27/2026 In EURm Revenues ▪ Increase driven by Medical Device Systems (MDS) with ramp-up of Peachtree Site in the US delivering results and strong sales performance out of Eastern European plants ▪ Advanced Technology / MDS: Closer collaboration around own device strategy ▪ Primary Plastic Packaging (PPP) & Centor approx. flat yoy +8.8%1 Revenues* Adj. EBITDA * 1 Organically, adjusted for exchange rate effects * including the business units currently in the sales process and before consolidation. Organic yoy Q1 2025 Prel. Q1 2026 281 296 52 61 Q1 2025 Prel. Q1 2026 Adj. EBITDA ▪ Solid sales to EBITDA fall through from MDS and Advanced Technology resource reductions in 2025 driving results yoy ▪ Softer PPP earnings from cash / inventory management18.5% 20.6% 8 Gerresheimer AG – Prelim. Q1 2026 Results Presentation
Page 10
Syringe systems topline growth offsets lower TG Europe & Asia performance Primary Injectable Solutions – Initiating TG Europe & Asia Restructuring 8/27/2026 In EURm Revenues ▪ Significant revenue growth in syringe systems >EUR 10m compensated by revenue decline in Tubular Glass Europe & Asia +14.2%1 Revenues* Adj. EBITDA * 1 Organically, adjusted for exchange rate effects * before consolidation. Organic yoy Q1 2025 Prel. Q1 2026 94 101 7 6 Q1 2025 Prel. Q1 2026 Adj. EBITDA ▪ Lower revenues in TG Europe & Asia resulted in negative EBITDA deviation vs Q1 25 ▪ Change in TG leadership and initiation of restructuring process with focus on footprint optimization, operational excellence and SG&A savings7.0% 5.7% 9 Gerresheimer AG – Prelim. Q1 2026 Results Presentation
Page 11
Topline decrease mainly US, closure Chicago Heights; lower Pharma in Europe and weaker Cosmetics Moulded Glass – Lower Sales Combined with Inventory Reduction Led to Low Asset Utilization impacting EBITDA 8/27/2026 In EURm Revenues ▪ Lower revenues in parenteral type 1 (Chicago Heights furnace repair) and type 3 pharma containers (Europe) were key drivers in combination with lower revenues (-9%) in Cosmetics due to weak market demand ▪ Initiated Chicago Heights plant closure; targeting completion by End of September; qualifying/transferring Type 1 US Glass customers at/to European and Asian plants -8.4%1 Revenues* Adj. EBITDA * 1 Organically, adjusted for exchange rate effects * before consolidation. Q1 2025 Prel. Q1 2026 160 144 6 Q1 2025 Prel. Q1 2026 32 Adj. EBITDA ▪ Inventory reduction in Q1 26 to address cash needs and the lower sales together causing a significant underutilization of assets with high fall through to adj. EBITDA ▪ Cash focus and inventory rigor included extended temporary production halts20.1% 4.5% 10 Organic yoy Gerresheimer AG – Prelim. Q1 2026 Results Presentation
Page 12
¹ Including leasing liabilities * including the business units currently in the sales process. Main drivers: Less inventory build-up through extended production halts and reducing capex to half Cash Rigor Paid Off: Best Q1 FCF* since 2019! with (€32m) and +€109m Improvement YoY 8/27/2026 66 25 -32 9 13 8 16 5 Prel. Adj. EBITDA Adjustments Δ NWC Net taxes paid Net interest paid Other Operating Cash Flow 57 Net Capex Prel. FCF before M&A Managed inventory build-up to EUR +5m only vs. EUR +46m last year; yoy EUR +41m swing Payables EUR -54m includes EUR -24m less reverse factoring line Strong receivables / collections efforts yielded EUR +46m on a yoy EUR +5m Sales increase Note: Q1 25 at EUR 113m = 2x By Type in Q1 26: -EUR ~19m base -EUR ~37m of growth By Segment in Q1 26: -EUR ~18m CDS -EUR ~26m PIS -EUR ~25m MG 4.4% average interest cost on avg. gross debt of EUR 2.2bn¹ 11 Q1 25 at EUR -141m; EUR +109m yoy improvement driven by: EUR -57m lower capex EUR -41m better inventory mgmt Gerresheimer AG – Prelim. Q1 2026 Results Presentation
Page 13
1 Drawn portion of the RCF 2 Includes: local credit facilities/overdraft facilities/factoring liabilities exceeding EUR 93m 3 Excluding lease liabilities up to EUR 93m 4 As per Q1 2026 but reflecting subsequent changes in Bridge and Term Loan Financing Solid liquidity in Q1 2026; leverage covenant suspended up and including Q3; fulsome debt refinancing at <3x leverage in process aligned with timing of Centor & PPP closing Financing as of Prel. Q1 2026 - Solid Liquidity and Refinancing in Process 8/27/2026 Net Financial Debt as of Preliminary Q1 2026 In EURm Prel. Q1 2026 Q4 2025 Q1 2025 Revolving credit facilities1 Bridge loan / term loans Promissory loans Local borrowings2 Cash + cash equivalents Net Financial Debt3 Liquidity Maturity Profile in EURm4 12 517 725 870 27 -184 1,955 342 480 725 870 22 -176 1,920 371 74 774 1,208 13 -151 1,919 751 158 75 100 100 675 192 184 525 347 257 Liquidity Q4 26 Q4 27 342 882 2028 2029 2030 2031 1,022 192 10075 Revolver Head Room Cash Promissory Loans Bridge Loan Revolver Term Loan Gerresheimer AG – Prelim. Q1 2026 Results Presentation
Page 14
Financial Reporting and Conferences August 27, 2026 Preliminary 1st Quarter 2026 Information September 1, 2026 Annual General Meeting 2026 September 2026 Publication Quarterly Statement for Q1 2026 November 2026 Publication Half-year Financial Report 2026 November 2026 Publication Quarterly Statement Q3 2026 Upcoming Events 8/27/2026 Financial Calendar Investor Conferences 2026 Kepler Cheuvreux Autumn Conference 2026 September 9, Paris Goldman Sachs 23rd Annual European Medtech and Healthcare Services Conference September 10, London Berenberg and Goldman Sachs 12th German Corporate Conference GCC September 22, Munich Baader Bank 14th Baader Investment Conference BIC September 23, München Berenberg Madrid Seminar October 1, Madrid 13 Gerresheimer AG – Prelim. Q1 2026 Results Presentation
Page 15
Roadmap defined to profitable High Value Primary Packaging and Drug Delivery Solutions Provider Closing Remarks and Next Steps 8/27/2026 • Execute Centor (Nov´26) and PPP (H1 27) sale to refinance at sustainable <3x leverage • Execute Transformation (gto) Initiatives ~50/50 ´26/27 for full run rate impact in ´28 • Prepare and sell Moulded Glass … Thank you for your continued support! 14 Gerresheimer AG – Prelim. Q1 2026 Results Presentation